Genelux

Genelux Enterprise Value

The Enterprise Value (EV) of Genelux (GNLX) as of Oct 18, 2026 is 103.81 M USD. In the previous year, Enterprise Value (EV) was 87.69 M USD — a change of 18.38% (higher).

Enterprise Value

103.81 MUSD

YoY

18.38%

Last updated:

Enterprise Value (EV) of Genelux is 2025 103.81 M USD. Enterprise Value (EV) of Genelux was 2024 87.69 M USD. It decreases by 18.38% higher compared to the previous year.

The Genelux Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2019
134.26 M USD
Jan 1, 2020
131.43 M USD
Jan 1, 2021
137.53 M USD
Jan 1, 2022
142.67 M USD
Jan 1, 2023
96.04 M USD
Jan 1, 2024
87.69 M USD
Jan 1, 2025
103.81 M USD
The Genelux Enterprise Value history
YEAREnterprise ValueYoY
103.81 MUSD+18.38%
87.69 MUSD-8.70%
96.04 MUSD-32.68%
142.67 MUSD+3.74%
137.53 MUSD+4.65%
131.43 MUSD-2.11%
134.26 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genelux Stock analysis

What does Genelux do? Genelux Corp, trading under the ticker GNLX, is a biotechnology company based in Westlake Village, California, operating within the Health Care sector. The company has 25 employees and completed its initial public offering on January 26, 2023. Genelux focuses on developing oncolytic viral immunotherapies for solid tumor cancers. Its lead product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a modified vaccinia virus (VACV), a stable DNA virus with significant engineering potential. The company is currently advancing Olvi-Vec through Phase II clinical trials for platinum-resistant or refractory ovarian cancer (PRROC). Additionally, Genelux is developing a platform called Virus and Vaccine (Neoantigen)-Enhanced Adoptive Cell Therapy (V2ACT), which aims to enhance cancer neoantigen-specific T cell activity within tumors. The company also has an animal health product candidate, V-VET1, a genetically characterized, veterinary-grade oncolytic vaccinia virus that is a naturally attenuated isolate. Genelux's website is https://genelux.com/ and it is registered with the ISIN US36870H1032. The company's operations and product development are centered on innovative viral-based therapies for both human and animal health applications. Genelux is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genelux stock

Enterprise Value (EV) of Genelux is 103.81 M USD in 2025.

Enterprise Value (EV) of Genelux changed from 87.69 M USD to 103.81 M USD, representing a 18.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Genelux since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Genelux with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Genelux

All Key Metrics — Genelux